-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
The researchers prospectively recruited 121 patients who had been diagnosed with primary aldosteronism, and they began treatment with a mineralocorticoid receptor antagonist (canrenone).
Eighteen patients (11 patients with unilateral hyperaldosteronism and 7 patients with bilateral primary hyperaldosteronism) formed a short-term study cohort, and the subjects' aldosterone was measured after 2 and 8 weeks of canrenone treatment , Renin and blood potassium levels.
After short-term and long-term treatment, the ratio of aldosterone to renin was significantly lower than that at baseline.
Screening diagnosis
Therefore, patients with hypertension should avoid using mineralocorticoid receptor antagonists before measuring renin and aldosterone levels to screen for primary aldosteronism .
Patients with hypertension should avoid mineralocorticoid receptor antagonists before measuring renin and aldosterone levels to screen for primary aldosteronism
Original source:
Original source:Alessio Pecori.
org/10.
1210/clinem/dgab290" target="_blank" rel="noopener">Mineralocorticoid receptor antagonist effect on aldosterone to renin ratio in patients with primary aldosteronism
in this message